Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by SunTrust Banks Inc. to a “reduce” rating in a research report issued on Tuesday. The firm presently has a $48.00 price objective on the stock, up from their previous price objective of $4.00. SunTrust Banks Inc.’s price target would indicate a potential downside of 1.92% from the company’s current price.

SRPT has been the topic of several other reports. Royal Bank Of Canada raised Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $5.00 to $83.00 in a research note on Monday. Leerink Swann reaffirmed an “underperform” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 4th. Vetr cut Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $17.28 price target on the stock. in a research note on Monday, May 23rd. Robert W. Baird reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a research note on Monday, July 18th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, July 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $46.40.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 14.109% during midday trading on Tuesday, hitting $55.845. The stock had a trading volume of 7,044,931 shares. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $56.18. The stock’s 50-day moving average is $27.32 and its 200-day moving average is $21.07. The stock’s market cap is $2.67 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/sarepta-therapeutics-inc-srpt-upgraded-by-suntrust-banks-inc-to-reduce.html

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the firm earned ($0.87) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post ($5.16) EPS for the current year.

In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 10.90% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the company. Harbour Capital Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter worth approximately $335,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock worth $2,934,000 after buying an additional 2,766 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock worth $441,000 after buying an additional 1,178 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter worth approximately $651,000. Finally, First Allied Advisory Services Inc. boosted its stake in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.